<HashMap><database>biostudies-arrayexpress</database><scores/><additional><submitter>Antonio Rinaldi</submitter><organism>Homo sapiens</organism><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/E-MTAB-15146</full_dataset_link><description>RNA-sequencing was performed on H1299, HEK293T and CHO-K1 transfected with plasmids expressing EGFP and mKate in an open loop circuit (OL), w/wo compound supplementation, or with iFFL circuit.mKate has target sites for miRNAs highly expressed in the different cell lines (miRNA31 for H1299, miRNA221 for HEK293T and miRNA21 for CHO-K1)</description><repository>biostudies-arrayexpress</repository><sample_protocol>Sample Treatment - Transfections were carried out in 24-well plate for flow cytometry analysis.   H1299 cells were transfected with Lipofectamine® 3000 according to manufacturer’s instructions and 300 ng of total DNA in 24-well plates. CHO and HEK293 were transfected with PEI transfection reagent with 300 ng of total DNA in 24-well plates. All cells were plated approximately 24h before transfection at 70000 to 80000 cells per well in 24-wells plates. At the moment of transfection, cells were put in starvation conditions, meaning in poor media for the first 24h. DNA was diluted in Opti-MEM reduced serum media (Gibco), before being mixed and incubated for 25 minutes prior to addition to the cells. All drugs were added 4h after transfection.  Modified-RNAs (modRNA) were transfected using Lipofectamine® 3000 protocol under modified conditions in which no P3000 reagent was used. RNA was first diluted in Opti-MEM reduced serum media (Gibco) and it was then mixed with diluted Lipofectamine reagent as manufacturer’s instructions. The mix was incubated for 7 minutes prior to addition to the cells. The fast-forward protocol was used by seeding 120000 cells per well in 24-wells plates at the moment of transfection.</sample_protocol><sample_protocol>Sequencing - Samples were processed with Illumina Novaseq6000</sample_protocol><sample_protocol>Library Construction - Libraries were prepared by Total RNAseq with ribo0 plus (Illumina)</sample_protocol><figure_sub>Organization</figure_sub><figure_sub>MINSEQE Score</figure_sub><figure_sub>Assays and Data</figure_sub><figure_sub>MAGE-TAB Files</figure_sub><data_protocol>Data Transformation - Sequence reads were trimmed using bbduk software to remove adapter sequences, poly-A tails and low-quality end bases. Alignment was performed with STAR on the Homo sapiens reference (hg38) provided by UCSC Genome Browser. The expression level of genes was determined with htseq-count using the Gencode/Ensembl gene model</data_protocol><omics_type>Metabolomics</omics_type><omics_type>Unknown</omics_type><omics_type>Transcriptomics</omics_type><omics_type>Genomics</omics_type><omics_type>Proteomics</omics_type><instrument_platform>Illumina NovaSeq 6000</instrument_platform><study_type>RNA-seq of coding RNA</study_type><species>Homo sapiens</species><pubmed_authors>Antonio Rinaldi</pubmed_authors></additional><is_claimable>false</is_claimable><name>Transcriptomic analysis of H1299, HEK293T and CHO-K1 treated with Filgotinib</name><description>RNA-sequencing was performed on H1299, HEK293T and CHO-K1 transfected with plasmids expressing EGFP and mKate in an open loop circuit (OL), w/wo compound supplementation, or with iFFL circuit.mKate has target sites for miRNAs highly expressed in the different cell lines (miRNA31 for H1299, miRNA221 for HEK293T and miRNA21 for CHO-K1)</description><dates><release>2025-07-24T00:00:00Z</release><modification>2025-07-24T07:41:28.408Z</modification><creation>2025-05-19T09:56:39.516Z</creation></dates><accession>E-MTAB-15146</accession><cross_references><ENA>ERP172710</ENA><Biostudies>E-MTAB-14355</Biostudies><EFO>EFO_0004170</EFO><EFO>EFO_0003816</EFO><EFO>EFO_0003738</EFO><EFO>EFO_0004184</EFO><EFO>EFO_0003969</EFO></cross_references></HashMap>